ArticleThe Journal of clinical investigation2009
MicroRNA reexpression as differentiation therapy in cancer.
Article in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 105 citations in OpenAlex.
- miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.The Journal of biological chemistry · 2014Trial
- Poly(lactide)-Based Materials Modified with Biomolecules: A Review.Materials (Basel, Switzerland) · 2024Review
- Non-coding RNA in rhabdomyosarcoma progression and metastasis.Frontiers in oncology · 2022Review
- Reduced expression of miR-30c-5p promotes hepatocellular carcinoma progression by targeting RAB32.Molecular therapy. Nucleic acids · 2021Article
- The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.Nutrients · 2021Review
- Reduced miR-16 levels are associated with VEGF upregulation in high-risk myelodysplastic syndromes.Journal of Cancer · 2021Article
- Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Application of atomic force microscope in diagnosis of single cancer cells.Biomicrofluidics · 2020Review
- Article
- Article
- A miR-206 regulated gene landscape enhances mammary epithelial differentiation.Journal of cellular physiology · 2019Article
- miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Investigation of PLGA nanoparticles in conjunction with nuclear localization sequence for enhanced delivery of antimiR phosphorothioates in cancer cells in vitro.Journal of nanobiotechnology · 2019Article
- Clinical significances and diagnostic utilities of both miR-215 and squamous cell carcinoma antigen-IgM versus alpha-fetoprotein in Egyptian patients with hepatitis C virus-induced hepatocellular carcinoma.Clinical and experimental gastroenterology · 2019Article
- MicroRNA-154 functions as a tumor suppressor in non-small cell lung cancer through directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1.Oncology letters · 2018Article
- Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection.Journal of nanobiotechnology · 2018Review
- Differentiation-inducing therapeutic effect of Notch inhibition in reversing malignant transformation of liver normal stem cells via MET.Oncotarget · 2018Article
- Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA.Drug delivery and translational research · 2018Article
- Induction of morphological and functional differentiation of human neuroblastoma cells by miR-124.Journal of biosciences · 2017Article
- MicroRNA-133b Inhibits Cell Proliferation and Invasion in Osteosarcoma by Targeting Sirt1.Oncology research · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Since their discovery in the early 2000s, microRNAs (miRNAs) and their penchant for RNA interference have taken the scientific community by storm, working their way into virtually every corner of biological inquiry. The very nature of their action, the ability to simultaneously extinguish the expression of a multitude of genes and negate their functions, immediately suggested therapeutic promise. In this issue of the JCI, a step toward the realization of this promise is described. Taulli et al. demonstrate that the miRNAs miR-1/miR-206, which are routinely lost in advanced, poorly differentiated rhabdomyosarcoma (RMS) but characteristically expressed in the mature skeletal muscle from which these tumors arise, restore the myogenic differentiation program and block the tumorigenic phenotype (see the related article beginning on page 2366). Their data support the notion that these small RNAs, effectively functioning as "micro-sheriffs" by restoring myogenic law and order, hold substantial clinical potential as differentiation therapy for RMS and perhaps other solid tumors. miRNA reexpression therapy constitutes a novel approach to handcuff oncogenes and arrest tumor development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.